AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|
17.3 C
New York
Wednesday, October 21, 2026

Tag: clinical trial

newsFORsourcecompanycontentinformation1releasesmarket

Ipsen – Half year statement – 2025 06 30

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved

National Heart, Lung, and Blood Institute / National Institutes of Health Signs Clinical Trial Agreement with Vascarta Inc. to Perform Phase 1 Clinical Study...

SUMMIT, N.J., July 7, 2025 /PRNewswire/ -- Under the agreement, the National Heart, Lung, and Blood Institute / National Institutes of Health will perform...

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients...

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/...

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs

New executives bring deep expertise to elevate quality and accelerate innovation across global operations SAN DIEGO, July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the...

First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.

Nuevocor Strengthens Board with Appointment of Thierry Abribat

SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr....

Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health

Human Clinical Trial of L-Ergothioneine (Dr.Ergo®) on Skin Health

Spectral Medical Inc. Announces Filing of Base Shelf Prospectus

TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “Securities Regulators”).

Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial

CINCINNATI, July 4, 2025 /PRNewswire/ -- During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus invading...

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.

BioDlink Drives Global Biologics Innovation with Ecosystem Partners

BioDlink convenes a peer advisory event bringing together biotech CEOs, MNC leaders and researchers to discuss innovation and collaboration strategiesIntegrated one-stop technology platform helps...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers